Targets of epigenetic therapy - Gene reactivation as a novel approach in MDS treatment

Cancer Treatment Reviews

Volumn 33, Issue SUPPL. 1, 2007, Pages

  Claus, R ^a   Ruter B ^a   Lubbert M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Chromatin; DNA methyltransferase; Histones; Myelodysplastic syndrome; Translocations

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEPSIPEPTIDE; DNA; DNA METHYLTRANSFERASE INHIBITOR; HEMOGLOBIN F; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PHENYLBUTYRATE SODIUM; PROTEIN P16INK4A; PROTEIN P300; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ARTICLE; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CPG ISLAND; DEACETYLATION; DNA METHYLATION; DNA REPAIR; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; EPIGENETICS; GENE ACTIVATION; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMAN; LOW DRUG DOSE; METHYLATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PROMOTER REGION; PROTEIN PROCESSING;

EID: 35848954082     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.07.009     Document Type: Article

References (40)

1. Baylin S.B. Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 12 (2002) 331-337
2. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., and Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72 (1998) 141-196
3. Issa J.P., Baylin S.B., and Herman J.G. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11 (1997) S7-S11
4. von Hoff D.D., and Slavik M. 5-azacytidine - a new anticancer drug with significant activity in acute myeloblastic leukemia. Adv Pharmacol Chemot 14 (1977) 285-326
5. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
6. Sorm F., Piskala A., Cihak A., and Vesely J. 5-azacytidine, a new, highly effective cancerostatic. Experientia 20 (1964) 202-203
7. Sorm F., and Vesely J. Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15 (1968) 339-343
8. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
9. Silverman L.R., Holland J.F., Weinberg R.S., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (1993) S21-S29
10. Silverman L.R., Holland J.F., and Demakos E.P. Azacitidine (AzaC) in myelodysplastic syndromes (MDS), CALGB Studies 8421 and 8921. Ann Hemat 68 (1994) S21a
11. Kornblith A.B., Herndon II J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20 (2002) 2441-2452
12. Maslak P., Chanel S., Camacho L.H., et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20 (2006) 212-217
13. Wijermans P.W., Krulder J.W., Huijgens P.C., and Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11 (1997) S19-S23
14. Wijermans P., Lübbert M., Verhoef G., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18 (2000) 956-962
15. Lübbert M., Wijermans P., Kunzmann R., et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114 (2001) 349-357
16. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 (2002) 5427-5440
17. Santini V., Kantarjian H.M., and Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134 (2001) 573-586
18. Chim C.S., Liang R., and Kwong Y.L. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 20 (2002) 167-176
19. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12 (1998) 845-859
20. Herman J.G., Civin C.I., Issa J.P., Collector M.I., Sharkis S.J., and Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57 (1997) 837-841
21. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., and Issa J.P. Methylation profiling in acute myeloid leukemia. Blood 97 (2001) 2823-2829
22. Uchida T., Kinoshita T., Nagai H., et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90 (1997) 1403-1409
23. Christiansen D.H., Andersen M.K., and Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17 (2003) 1813-1819
24. Quesnel B., Guillerm G., Vereecque R., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91 (1998) 2985-2990
25. Daskalakis M., Nguyen T.T., Nguyen C., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100 (2002) 2957-2964
26. Gore S.D., Baylin S., Sugar E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66 (2006) 6361-6369
27. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004) 1635-1640
28. Mund C., Hackanson B., Stresemann C., Lübbert M., and Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 65 (2005) 7086-7090
29. Mavilio F., Giampaolo A., Care A., et al. Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts. Proceedings of the National Academy of Sciences of the United States of America 80 (1983) 6011-6907
30. Ley T.J., DeSimone J., Anagnou N.P., et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. New Engl J Med 307 (1982) 1469-1475
31. Ley T.J., DeSimone J., Noguchi C.T., et al. 5-azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62 (1983) 370-380
32. Tan G.B., Aw T.C., Dunstan R.A., and Lee S.H. Evaluation of high performance liquid chromatography for routine estimation of haemoglobins A2 and F. J Clin Pathol 46 (1993) 852-856
33. Santos-Rosa H., and Caldas C. Chromatin modifier enzymes, the histone code and cancer. Eur J Cancer 41 (2005) 2381-2402
34. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32 (2004) 959-976
35. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nature Rev 1 (2001) 194-202
36. Grewal S.I., and Rice J.C. Regulation of heterochromatin by histone methylation and small RNAs. Curr Opin Cell Biol 16 (2004) 230-238
37. Meyer C., Schneider B., Jakob S., et al. The MLL recombinome of acute leukemias. Leukemia 20 (2006) 777-784
38. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21 (1999) 103-107
39. Garcia-Manero G., Kantarjian H., Sanchez-Gonzalez B., et al. Final results of a Phase I/II study of the combination of the Hypomethylating agent 5-aza-2′-Deoxycytidine (DAC) and the histone deacetylase inhibitor valproic acid (VPA) in patients with leukemia. Blood 106 (2005) 408
40. Garcia-Manero G., Yang H., Sanchez-Gonzalez B., et al. Final results of a Phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide hydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome. Blood 106 (2005) 2801